Find a Clinical Trial

Showing 161 - 170 of 174 Trials

  • Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A PilotStudy

    Principal Investigator:

    Brian Henick, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06673329

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to...

  • A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT07174583

    Population:

    Adult

    Phase:

    NA
    This is a research study that includes studying IDE849 in small cell lung cancer (SCLC) that has progressed or recurred (returned) after previous standard treatment. The purpose of this study is to determine the highest dose of IDE849 that can be safely given to participants. The study drug used in this study is called IDE849. The study drug will be given through an intravenous (IV - into the vein) infusion on a slow drip. Study drug will be given once every 3 weeks in 21-day cycles. IDE849 is an experimental drug that is not approved by the Food and Drug Administration (FDA). This research...

  • DISRUPT: Aim 2

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05146297

    Population:

    Adult

    Phase:

    NA
    That Black, Indigenous, and People of Color (BIPOC) are more likely to die from their cancer is well known. Despite years of progress in cancer research and treatment, most research is done in white populations. For this reason, it is not certain how best to treat BIPOC with cancer. The number of people with cancer who join a clinical trial (CT) in the United States at 8%. This low number is due to many reasons including the things related to the healthcare system, the number and type of clinical trials that are available, and the other illnesses patients have. These factors affect BIPOC...

  • Electronic health record-based implementation strategies and decision support for hereditary breast and ovarian cancer genetic testing among multiethnic women (ELISABETH)

    Principal Investigator:

    Katherine D Crew, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    The purpose of this research study is to test how well a new approach—using tools built into the electronic health record (EHR)—can help increase genetic testing for hereditary breast and ovarian cancer (HBOC) in women who have a family history that puts them at higher risk. The study will also look at what helps or gets in the way of using these tools in everyday clinical care. As part of this study, we are also evaluating a website called RealRisks, which is designed to support patients in understanding their risk and making informed decisions about genetic testing. By studying...

  • Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and to Reduce Refills after Cancer-Related Surgery

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05585788

    Population:

    Adult

    Phase:

    NA
    - Are you of 18 years or older? - Do you have upcoming open, non-laparoscopic surgery? - Is it planned that you will receive opioids in the post-operative period? - Are you able to download and use a iPhone or iPad application? Are you Eligible? (Inclusion Criteria) Are you of 18 years or older? Do you have upcoming open, non-laparoscopic surgery? Is it planned that you will receive opioids in the post-operative period? Are you able to download and use a iPhone or iPad application?

  • Feasibility Study of Adaptive Radiotherapy for the Treatment of Locally-Advanced Anal Squamous Cell Carcinoma

    Principal Investigator:

    Lisa Ann Kachnic, MD, FASTRO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05838391

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to find out if performing adaptive planning during the treatment anal cancer will decrease the dose of radiation to normal organs and decrease the side effects. In this study, subjects will have a daily adjustment (adaptation) of their radiation plan as the tumor changes during the radiation treatment. The radiation will be given as part the standard of care treatment with chemotherapy, known as chemo-RT (CRT). Are you Eligible? (Inclusion Criteria) To be considered for this study, you must: 1. Have invasive anal cancer confirmed with biopsy 2. Be greater than 18...

  • Improving Medications Adherence Equitably among Patients with Metastatic Breast Cancerand Cardiovascular Disease

    Principal Investigator:

    Claire Sathe, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06121453

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to evaluate the effect of a multi-part intervention to reduce barriers to medication use. All subjects who are enrolled in the study will undergo the following interventions: 1) A complete medication reconciliation will be done where you will be asked about all current medication you have been prescribed. This is to create an accurate list of current medications you are taking. 2) A two-time visit with a pharmacist to review all the medicines you take, reasons for not taking medicines, and to create a personalized plan to help you take your medicines. After 4...

  • IMPACT Trial: Intervention to iMProve AdherenCe equitably

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05496829

    Population:

    Adult

    Phase:

    NA
    Many patients with breast cancer, who also take medicine to prevent heart disease such as a blood pressure medicine or a cholesterol medicine, experience frustration with the large number and difficult scheduling of their medications, known as “pill burden”. This study will help us find out how much “pill burden” exists in subjects with cancer at various stages, and how this intervention can help. Results of this study may help us figure out the best way to help patients manage their medications in the future. Are you Eligible? (Inclusion Criteria) Are you diagnosed...

  • Pilot Study to Assess Feasibility, Acceptability, and Efficacy of a Food Navigation and Food DeliveryIntervention to Reduce Food Insecurity Among Patients with Metastatic Breast Cancer

    Principal Investigator:

    Claire Sathe, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    The purpose of this research study to find out how we can best help patients with metastatic (advanced) breast cancer who sometimes worry not having enough food and provide resources to access the food that they need. We want to test an intervention by taking surveys to determine how it affects the patients, their food environment, and their mental health. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have access to smartphone, tablet, or any type of telephone to complete surveys - Must be able to speak English or Spanish

  • Post-marketing surveillance of StrataCTX® flexible wound dressing for use as a steroid sparing agent

    Principal Investigator:

    Larisa J Geskin, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04087629

    Population:

    Adult

    Phase:

    NA
    To assess the use of StrataCTX® as a steroid sparing agent for disorders usually treated with topical steroids. Are you Eligible? (Inclusion Criteria) Age ≥ 18 years Ability to sign informed consent document Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel Patients with a diagnosis of CTCL who have intractable pruritus Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief Patients on chemo/immunotherapy with drug induced rash Patients with cutaneous acute graft versus host disease

Pages